Bolt Biotherapeutics IncNASDAQ:BOLTNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.5668
- TODAY'S CHANGE (%)-0.0032 (-0.5614%)
- Bid / Lots0.5510/ 100
- Ask / Lots0.5950/ 49
- Open / Previous Close0.5655 / 0.5700
- Day Range
- 52 Week Range
- Volume80,916
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BOLT |
|---|---|---|
| 09:32 ET | 150 | 0.5655 |
| 09:44 ET | 500 | 0.559799 |
| 09:51 ET | 1000 | 0.5597 |
| 09:53 ET | 4034 | 0.5795 |
| 10:04 ET | 199 | 0.5513 |
| 10:09 ET | 200 | 0.556 |
| 10:40 ET | 199 | 0.56 |
| 10:42 ET | 3600 | 0.563236 |
| 10:45 ET | 100 | 0.578 |
| 11:03 ET | 100 | 0.577 |
| 11:12 ET | 188 | 0.578 |
| 11:14 ET | 314 | 0.57 |
| 11:23 ET | 100 | 0.577 |
| 11:30 ET | 1100 | 0.5789 |
| 11:36 ET | 200 | 0.57144 |
| 11:41 ET | 5167 | 0.57 |
| 11:43 ET | 284 | 0.579 |
| 11:52 ET | 1213 | 0.57 |
| 11:54 ET | 250 | 0.574449 |
| 12:01 ET | 420 | 0.575 |
| 12:03 ET | 276 | 0.5701 |
| 12:08 ET | 1047 | 0.5695 |
| 12:10 ET | 300 | 0.56715 |
| 12:17 ET | 5007 | 0.56 |
| 12:26 ET | 1300 | 0.572558 |
| 01:24 ET | 250 | 0.567 |
| 01:42 ET | 100 | 0.574 |
| 01:49 ET | 8900 | 0.56 |
| 02:09 ET | 222 | 0.56 |
| 02:16 ET | 100 | 0.571 |
| 02:27 ET | 9388 | 0.56 |
| 02:30 ET | 1512 | 0.56 |
| 02:32 ET | 3231 | 0.572 |
| 02:38 ET | 100 | 0.5513 |
| 03:01 ET | 1700 | 0.56 |
| 03:03 ET | 10105 | 0.5744 |
| 03:12 ET | 2800 | 0.55905 |
| 03:32 ET | 4319 | 0.5611 |
| 03:33 ET | 5771 | 0.5668 |
| 03:42 ET | 400 | 0.561 |
| 03:48 ET | 100 | 0.5668 |
| 03:51 ET | 100 | 0.5639 |
| 03:53 ET | 250 | 0.5668 |
Nov 12, 2024
Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones*DJ Bolt Biotherapeutics 3Q Loss/Shr 40c >BOLT, from 4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 7, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Bolt Biotherapeutics Inc | 21.7M | -0.3x | --- |
Pulmatrix Inc | 22.3M | -2.3x | --- |
DURECT Corp | 26.8M | -1.6x | --- |
Spruce Biosciences Inc | 20.3M | -0.5x | --- |
Aspira Women's Health Inc | 12.0M | -0.5x | --- |
Tonix Pharmaceuticals Holding Corp | 38.2M | 0.0x | --- |
Company Information
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The Company's pipeline candidates are built on its expertise in myeloid biology and cancer drug development. Its pipeline includes trastuzumab imbotolimod (formerly BDC-1001), a human epidermal growth factor receptor 2 - targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. Trastuzumab imbotolimod is in Phase 2 clinical. BDC-3042, an agonist antibody targeting Dectin-2, is in a Phase 1 dose-escalation trial. In preclinical development, BDC-3042 demonstrated the ability to convert tumor-supportive macrophages to tumor-destructive macrophages. It developed a lead agonist antibody that binds to Dectin-2 and activates human tumor-associated macrophages. It is developing multiple Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Contact Information
- Headquarters
- 900 Chesapeake DriveREDWOOD CITY, CA, United States 94063
- Phone
- 650-665-9295
- Fax
- 302-531-3150
Executives
- President, Chief Executive Officer, Chief Financial Officer, Director
- William Quinn
- Chief Operating Officer
- Grant Yonehiro
- Director
- Jakob Dupont
- Independent Director
- Laura Berner
- Independent Director
- Kathleen Laporte
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $21.7M |
|---|---|
Revenue (TTM) | $9.8M |
Shares Outstanding | 38.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.89 |
EPS | $-1.71 |
Book Value | $2.96 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 2.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -728.33% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
